Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL23149100

FC(F)(F)Oc1ccc(COC2CNC2)cc1.O=C(O)C(F)(F)F

nearest known ligand 0.49

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 2/20 0.49
SLC6A4 P31645 2/20 0.49
CARM1 Q86X55 1/20 0.46
PRMT6 Q96LA8 1/20 0.46
CHRM1 P11229 1/20 0.41
MRGPRX4 Q96LA9 1/20 0.40
EPHX2 P34913 3/20 0.39
LTA4H P09960 1/20 0.39
PTPN1 P18031 1/20 0.39
FFAR1 O14842 1/20 0.39
FFAR4 Q5NUL3 1/20 0.39
PPARG P37231 1/20 0.39
PPARA Q07869 1/20 0.39
NR1H4 Q96RI1 1/20 0.39
GPR84 Q9NQS5 1/20 0.39
HRH3 Q9Y5N1 1/20 0.39
MAPK8 P45983 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3128895 0.90 SLC6A4 (0.56) HTR2CSLC6A4CARM1PRMT6CHRM1
Trifluoroacetic Acid SCHEMBL31071587 0.86 SLC6A4 (0.54) SLC6A4CARM1PRMT6MRGPRX4FFAR1
Trifluoroacetic Acid SCHEMBL23149062 0.86 LMNA (0.43) HTR2CSLC6A4MRGPRX4PPARGPPARA
Trifluoroacetic Acid SCHEMBL20451601 0.84 NAAA (0.48) FFAR1
SCHEMBL27154213 0.79 BCHE (0.52) HTR2CSLC6A4CARM1PRMT6CHRM1
SCHEMBL27144034 0.77 CARM1 (0.49) CARM1PRMT6CHRM1MRGPRX4EPHX2
SCHEMBL2301027 0.76 CARM1 (0.56) HTR2CSLC6A4CARM1PRMT6CHRM1
SCHEMBL2297744 0.75 CARM1 (0.59) CARM1PRMT6CHRM1EPHX2HRH3
Hydrochloric Acid SCHEMBL13734341 0.75 CARM1 (0.55) HTR2CSLC6A4CARM1PRMT6CHRM1
SCHEMBL31071605 0.75 SLC6A4 (0.62) SLC6A4CARM1PRMT6CHRM1FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4034538-A1 NEW HETEROCYCLIC MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS F. Hoffmann-La Roche AG (CH) 2022-08-03 EP disclosed
CN-114401968-A Novel heterocyclic monoacylglycerol lipase (MAGL) inhibitors 豪夫迈·罗氏有限公司 2022-04-26 CN disclosed
WO-2021058445-A1 NEW HETEROCYCLIC MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2021-04-01 WO disclosed
US-20210094973-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2021-04-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210094973-A1 HETEROCYCLIC COMPOUNDS H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP1A1, CYP1B1 HTR2C 864/4885SLC6A4 3942/4885CARM1 291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.